Guidant Ancure
This article was originally published in The Gray Sheet
Executive Summary
AAA endovascular graft will return to the U.S. market this quarter, following FDA approval of a PMA supplement allowing the company to proceed with full market release, company announces Aug. 17. Guidant President and CEO Ronald Dollens says he expects the abdominal aortic aneurysm repair device to realize previous sales levels "within one to two quarters" of launch. The Ancure underwent a worldwide recall on March 16 following reports of deployment problems with the minimally invasive system (1"The Gray Sheet" March 19, 2001, p. 24)